BioCardia, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 19, 2019 and accepted by EDGAR at Nov 19, 2019, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $194.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $495.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $24.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $321.0k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $6.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2019-07-01 to 2019-09-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-30 | $4.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$10.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-07-01 to 2019-09-30 | $112.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2019-01-01 to 2019-09-30 | $112.0k | us-gaap:InterestExpense |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$3.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$11.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.63 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$2.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$6.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $144.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $8.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $9.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $10.7m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $4.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $5.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | $5.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-19-023200. Last ingested by Listed: Nov 10, 2026, 21:12 ET. Listed shows no prices and gives no investment advice.